Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3428 - Surgical quality and the impact of liver resection on outcome in the New EPOC study


09 Sep 2017


Poster display session


Surgical Oncology;  Radiation Oncology;  Colon and Rectal Cancer


Sian Pugh


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


S. Pugh1, J. Bridgewater2, M. Finch-Jones3, M. Rees4, D. O'Reilly5, M. Peterson6, B. Davidson7, R. Hutchins8, N. Heaton9, L.R. Jiao10, S. Mudan11, A. Allen12, J. Mellor13, G. Griffiths14, D. Cunningham15, T. Maughan16, J. Garden17, J. Primrose18

Author affiliations

  • 1 Surgery, University of Southampton, SO166YD - Southampton/GB
  • 2 Medical Oncology, UCL Cancer Institute/Paul O'Gorman Building, WC1E 6DD - London/GB
  • 3 Surgery, University Hospitals Bristol NHS Foundation Trust, Bristol/GB
  • 4 Surgery, Hampshire Hospitals NHS Foundation Trust, Basingstoke/GB
  • 5 Surgery, North Manchester General Hospital, London/GB
  • 6 Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield/GB
  • 7 Surgery, Royal Free Hospital and University College of London, London/GB
  • 8 Surgery, Barts Health NHS Trust, London/GB
  • 9 Surgery, King’s College Hospital NHS Foundation Trust, London/GB
  • 10 Surgery, Hammersmith Hospital, Imperial College, London/GB
  • 11 Surgery, The Royal Marsden Hospital NHS Foundation Trust, London/GB
  • 12 Clinical Trials Unit, University of Southampton, 1B - Southampton/GB
  • 13 Southampton Clinical Trials Unit, University of Southampton, SO17 1BJ - Southampton/GB
  • 14 Clinical Trials Unit, University of Southampton, SO17 1BJ - Southampton/GB
  • 15 Gi And Lymphoma Research Unit, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 16 Oncology, Oxford Institute for Radiation Oncology, OX3 7DQ - Oxford/GB
  • 17 Surgery, University of Edinburgh, Edinburgh/GB
  • 18 Surgery, University of Southampton, SO17 1BJ - Southampton/GB


Abstract 3428


The New EPOC study demonstrated a shorter progression-free survival (PFS) with the addition of cetuximab to chemotherapy for operable colorectal liver metastasis. The combination of a liver resection with EGFR inhibition is unique to this study. This analysis explores both surgical quality and the impact of volume of liver resected on outcome.


Data is presented for 263/271 patients (early study withdrawals excluded). Details of surgery were completed by the operating or lead surgeon in 19 UK specialist centres. The report of no residual tumour in the pathological specimen was queried in each case. Volume of liver resected was estimated and patients divided into tertiles (tertile 1: ≤20.5%, tertile 2 20.6-44.1%, tertile 3: 44.2-84.8%) to investigate association with PFS.


Operations were performed on 233/263 patients (118 chemo alone CT, 115 chemo and cetuximab CTX) of which 205 (108 CT, 97 CTX) underwent resection. A further 18 had surgery that included ablation (6 CT, 12 CTX). 155 had major resections (87 CT, 68 CTX) and the median estimated volume of total liver volume resected was the same in both groups (CT 27.8% IQR 17.0-63.4, CTX 27.8% 17.4-63.4). In the CT group PFS was significantly associated with the volume of liver resected (tertile 1 median PFS not reached, tertile 2 28 months, tertile 3 18.7 months, p = 0.02). Those with a smaller resection volume (tertile 1, ≤20%) appeared to have a shorter PFS with cetuximab (median PFS for CT not reached, CTX 15.2 months, HR 2.15 95%CI 1.00-4.57 p = 0.06). By contrast those with a larger volume of liver resected (tertiles 2 & 3) had similar outcomes irrespective of the use of cetuximab (median PFS for CT 20.2 months, CTX 16.9 months, HR 1.06 95%CI 0.65-1.71 p = 0.83). When analysis was restricted to just those with a R0 resection the shorter PFS with cetuximab persisted (HR 1.68 95% CI 1.04-2.71 p = 0.035). Examination of the pathological specimen revealed no residual tumour in 22 patients (14 CT, 8 CTX) of whom 8 have disease progression (6 CT, 2 CTX).


These exploratory analyses suggest the technical aspects of surgery are similar between the treatment groups and that those patients having smaller volume resections may be disadvantaged by the addition of cetuximab.

Clinical trial identification

ISRCTN 22944367

Legal entity responsible for the study

University Hospital Southampton NHS Foundation Trust


Cancer Research UK


D. O\'Reilly: Received expenses, travel, accommodation or otherwise, from AngioDynamics and Mylan. M. Peterson: Received expenses, travel, accommodation or otherwise, from TeleFlex. N. Heaton: Has provided and been paid, including honoraria, for consulting and/or advisory roles and participating in a speakers\' bureau by Astellas. Has a patent or other royalties/intellectual property under his own account. G. Griffiths: Has provided and been paid for consulting and/or advisory roles for the following companies in the past two years: Sirtex, Celgene, GSK. D. Cunningham: Has conducted research projects on behalf of his institution which have been funded, in whole or in part, by the following companies: Amgen, AstraZeneca, Bayer, Celgene, Merrimack, Medimmune, Merck Serono and Sanofi. T. Maughan: Has provided and been paid for consulting and/or advisory roles for the following company in the past two years: Vertex. J. Garden: Participated in a speakers\' bureau for a Johnson and Johnson (Ethicon) workshop (May 2016). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.